全文获取类型
收费全文 | 2581951篇 |
免费 | 189285篇 |
国内免费 | 7557篇 |
专业分类
耳鼻咽喉 | 34272篇 |
儿科学 | 85197篇 |
妇产科学 | 71567篇 |
基础医学 | 363549篇 |
口腔科学 | 69644篇 |
临床医学 | 234283篇 |
内科学 | 515033篇 |
皮肤病学 | 62450篇 |
神经病学 | 213384篇 |
特种医学 | 99881篇 |
外国民族医学 | 736篇 |
外科学 | 386424篇 |
综合类 | 50386篇 |
现状与发展 | 5篇 |
一般理论 | 968篇 |
预防医学 | 195937篇 |
眼科学 | 56617篇 |
药学 | 187966篇 |
8篇 | |
中国医学 | 5337篇 |
肿瘤学 | 145149篇 |
出版年
2021年 | 20019篇 |
2019年 | 20631篇 |
2018年 | 29293篇 |
2017年 | 22601篇 |
2016年 | 26232篇 |
2015年 | 29524篇 |
2014年 | 40459篇 |
2013年 | 60458篇 |
2012年 | 80282篇 |
2011年 | 84543篇 |
2010年 | 51028篇 |
2009年 | 49161篇 |
2008年 | 79052篇 |
2007年 | 83883篇 |
2006年 | 85591篇 |
2005年 | 81751篇 |
2004年 | 78746篇 |
2003年 | 76059篇 |
2002年 | 73354篇 |
2001年 | 128426篇 |
2000年 | 131353篇 |
1999年 | 110514篇 |
1998年 | 31259篇 |
1997年 | 27925篇 |
1996年 | 28221篇 |
1995年 | 27389篇 |
1994年 | 25075篇 |
1993年 | 23426篇 |
1992年 | 85165篇 |
1991年 | 81569篇 |
1990年 | 78787篇 |
1989年 | 76063篇 |
1988年 | 69475篇 |
1987年 | 68000篇 |
1986年 | 63549篇 |
1985年 | 60513篇 |
1984年 | 44944篇 |
1983年 | 37944篇 |
1982年 | 22459篇 |
1981年 | 19985篇 |
1979年 | 38961篇 |
1978年 | 27441篇 |
1977年 | 23255篇 |
1976年 | 21496篇 |
1975年 | 22815篇 |
1974年 | 26791篇 |
1973年 | 25377篇 |
1972年 | 23756篇 |
1971年 | 21959篇 |
1970年 | 20187篇 |
排序方式: 共有10000条查询结果,搜索用时 562 毫秒
281.
Rian M. Hasson Kayla A. Fay Joseph D. Phillips Timothy M. Millington David J. Finley 《American journal of surgery》2021,221(4):725-730
BackgroundRural populations face many health disadvantages compared to urban areas. There is a critical need to better understand the current lung cancer screening landscape in these communities to identify targeted areas to improve the impact of this proven tool.MethodsData from the County Health Rankings of New Hampshire and Vermont was reviewed for population density, distribution of adult smokers, and level of education compared to the distribution of Lung Cancer Screening Facilities throughout these two states.ResultsScreening programs in southern counties of Vermont with lower levels of education have decreased access. In New Hampshire, there are no programs within 30 miles of the areas with the largest distribution of smokers, and decreased access in some areas with the lowest levels of education.ConclusionsImproving equitable access to high-quality screening services in rural regions and the creation of targeted interventions to address decreased access in areas of high tobacco use and low education is vital to decreasing the incidence of latestage presentations of lung cancer within these populations. 相似文献
282.
Erik de Bakker Mirthe A. M. van der Putten Martijn W. Heymans Sander W. Spiekstra Taco Waaijman Liselotte Butzelaar Vera L. Negenborn Vivian K. Beekman Erman O. Akpinar Thomas Rustemeyer Frank B. Niessen Susan Gibbs 《Experimental dermatology》2021,30(1):169-178
Unpredictable hypertrophic scarring (HS) occurs after approximately 35% of all surgical procedures and causes significant physical and psychological complaints. Parallel to the need to understanding the mechanisms underlying HS formation, a prognostic tool is needed. The objective was to determine whether (systemic) immunological differences exist between patients who develop HS and those who develop normotrophic scars (NS) and to assess whether those differences can be used to identify patients prone to developing HS. A prospective cohort study with NS and HS groups in which (a) cytokine release by peripheral blood mononuclear cells (PBMC) and (b) the irritation threshold (IT) after an irritant (sodium lauryl sulphate) patch test was evaluated. Univariate regression analysis of PBMC cytokine secretion showed that low MCP‐1, IL‐8, IL‐18 and IL‐23 levels have a strong correlation with HS (P < .010‐0.004; AUC = 0.790‐0.883). Notably, combinations of two or three cytokines (TNF‐a, MCP‐1 and IL‐23; AUC: 0.942, Nagelkerke R2: 0.727) showed an improved AUC indicating a better correlation with HS than single cytokine analysis. These combination models produce good prognostic results over a broad probability range (sensitivity: 93.8%, specificity 86.7%, accuracy 90,25% between probability 0.3 and 0.7). Furthermore, the HS group had a lower IT than the NS group and an accuracy of 68%. In conclusion, very fundamental immunological differences exist between individuals who develop HS and those who do not, whereas the cytokine assay forms the basis of a predictive prognostic test for HS formation, the less invasive, easily performed irritant skin patch test is more accessible for daily practice. 相似文献
283.
Shylo R. Johnson Dennis Slate Kathleen M. Nelson Amy J. Davis Samual A. Mills John T. Forbes Kurt C. VerCauteren Amy T. Gilbert Richard B. Chipman 《Viruses》2021,13(2)
Since the 1990s, oral rabies vaccination (ORV) has been used successfully to halt the westward spread of the raccoon rabies virus (RV) variant from the eastern continental USA. Elimination of raccoon RV from the eastern USA has proven challenging across targeted raccoon (Procyon lotor) and striped skunk (Mephitis mephitis) populations impacted by raccoon RV. Field trial evaluations of the Ontario Rabies Vaccine Bait (ONRAB) were initiated to expand ORV products available to meet the rabies management goal of raccoon RV elimination. This study describes the continuation of a 2011 trial in West Virginia. Our objective was to evaluate raccoon and skunk response to ORV occurring in West Virginia for an additional two years (2012–2013) at 75 baits/km2 followed by three years (2014–2016) of evaluation at 300 baits/km2. We measured the change in rabies virus-neutralizing antibody (RVNA) seroprevalence in targeted wildlife populations by comparing levels pre- and post-ORV during each year of study. The increase in bait density from 75/km2 to 300/km2 corresponded to an increase in average post-ORV seroprevalence for raccoon and skunk populations. Raccoon population RVNA levels increased from 53% (300/565, 95% CI: 50–57%) to 82.0% (596/727, 95% CI: 79–85%) during this study, and skunk population RVNA levels increased from 11% (8/72, 95% CI: 6–20%) to 39% (51/130, 95% CI: 31–48%). The RVNA seroprevalence pre-ORV demonstrated an increasing trend across study years for both bait densities and species, indicating that multiple years of ORV may be necessary to achieve and maintain RVNA seroprevalence in target wildlife populations for the control and elimination of raccoon RV in the eastern USA. 相似文献
284.
Prevention Science - This study aimed to evaluate the effectiveness of the drug and violence resistance educational program (PROERD) on short-term secondary outcomes, such as intentions to use... 相似文献
285.
286.
287.
288.
A. Cattapan K. Browne D.M. Halperin A. Di Castri P. Fullsack J. Graham J.M. Langley B.A. Taylor S.A. McNeil S.A. Halperin 《Vaccine》2019,37(2):289-295
Introduction/Hypothesis
Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.Methods
An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.Results
A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.Conclusions/Recommendations
Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial. 相似文献289.
290.